SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What Is Metisl2 (METIS)? Metis: A Multi-Network Ecosystem Redefining Decentralized Infrastructure​ Metis is more than a Layer 2 - it is a multi-network ecosystem powered by the groundbreaking MetisSDK. Metis is building the future of decentralized infrastructure with a dual-network architecture: Andromeda for secure, general-purpose dApps and Hyperion for high-performance, AI-optimized execution. Both chains interoperate seamlessly, enabling builders to deploy scalable, efficient, and intelligent Web3 applications across sectors such as DeFi, gaming, DEPIN and AI.  What Is Andromeda ? Andromeda​​ serves as the foundational optimistic rollup network within the Metis ecosystem, delivering scalable decentralized infrastructure with Ethereum-level security and enhanced throughput. Optimized for DeFi, gaming, and general-purpose applications, it leverages a decentralized sequencer network and fraud-proof mechanisms to prioritize reliability and proven execution over extreme performance. Its battle-tested architecture supports a growing ecosystem of protocols requiring robust security models.  Andromeda will evolve alongside Hyperion, maintaining its core focus on secure general-purpose infrastructure. Key upgrades like on-chain data availability and fraud-proof refinements will advance its capabilities, with a roadmap targeting Stage 0 deployment soon and Stage 1 completion by year-end. As Metis’ cornerstone network, it remains the go-to solution for projects valuing decentralization (via full DSEQ nodes) and time-tested security frameworks.   What Is Hyperion ? Hyperion：The First Layer 2 Bringing On-Chain LLMs to Life Hyperion is a high-performance, AI-optimized Layer 2 solution designed to scale AI, DeFi, Depin and gaming applications. It enhances Metis' ecosystem by introducing parallel execution, AI-native infrastructure and decentralized sequencing, while maintaining Ethereum security and METIS as the gas token.  Hyperion, developed with the powerful MetisSDK and LazAI’s Alith AI framework, is the first Layer 2 Ethereum-compatible solution designed explicitly for on-chain AI execution, notably supporting Large Language Models (LLMs). It combines blockchain’s decentralized trust and transparency with AI's analytical and predictive powers, delivering an unparalleled user and developer experience.  This architecture optimizes the execution efficiency of AI processes within blockchain ecosystems, reducing computational overhead while maintaining network integrity. By embedding Alith’s modular framework for seamless AI/blockchain interoperability, Hyperion establishes a robust technical bridge between artificial intelligence and distributed ledger technologies.  This advancement fundamentally enhances decentralized application (dApp) capabilities, unlocking new possibilities for complex AI-driven functionalities in Web3 environments.  ✅ Key Features of Hyperion (HYPE):  Parallelized Transactions for Hyper-Scalability Hyperion’s Parallel Execution Engine, paired with an Optimistic Rollup model, processes multiple transactions simultaneously, delivering sub-second finality. Optimized fraud-proof mechanisms ensure security without sacrificing speed, making Hyperion perfect for real-time AI, gaming, and DeFi applications.  High Performance On-chain LLMS Inference By leveraging Rust's performance advantages and quick model inference technologies, Alith ensures that AI tasks in MetisSDK are executed efficiently, even under high transaction volumes. Revolutionizing Storage MetisDB eliminates storage bottlenecks with memory-mapped Merkle Trees, multi-version concurrency control, and asynchronous I/O processing. This ensures lightning-fast data access and cost-efficient state management, critical for data-intensive AI applications. AI-Optimized Powerhouse Hyperion’s Metis Virtual Machine (MetisVM) is custom-built for on-chain AI inference and high-throughput dApps. With dynamic opcode optimization, speculative parallel execution, and state-aware caching, MetisVM slashes gas fees and boosts processing speeds, enabling developers to run machine learning models directly on-chain. Seamless Ethereum and Cross-Chain Integration Hyperion commits state changes to Ethereum for battle-tested security while enabling cross-chain liquidity through a shared bridge framework. Integration with off-chain compute networks allows AI developers to leverage distributed processing power, creating scalable, interoperable dApps.  Why Choose Hyperion? Hyperion isn’t just another Layer 2 solution - it’s a revolutionary leap forward in how blockchain and AI interact. By placing high-performance, secure AI processes directly onto the blockchain, Hyperion reduces reliance on centralized systems, enhances transparency, and empowers developers and users alike.  This combination of scalability, efficiency, and high-performance inference positions Hyperion as the optimal choice for developers aiming to build next-generation decentralized applications.  The Hyperion Testnet Launch: Experience the Future Today Hyperion testnet launch invites AI developers, blockchain enthusiasts, Web3 developers, and tech innovators to explore, test, and innovate. Join us in pioneering a smarter, more intelligent blockchain ecosystem.  Hyperion is more than just an upgrade - it's the future of blockchain intelligence.  Access the Testnet: Visit https://hyperion.metis.io dive into Hyperion’s AI-optimized infrastructure. Explore Documentation: Find technical specs and developer resources at http://docs.metis.io/hyperion

Metis Token

Metis (METIS) is trending as an Ethereum Layer 2 solution, drawing significant attention for its advanced AI integration efforts, including its Hyperion L2 and MetisSDK for AI-native dApps. The community is actively discussing its potential for substantial price movement, frequently highlighting its low token supply and ongoing advancements in decentralized sequencers. Many in the community also note its unique connection to Ethereum's co-founder as a point of interest.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is trending due to excitement over its Legend app launch and nearing max token supply, sparking hopes for a supply shock and potential fintech integrations within the DeFi sector. However, community discussion is sharply divided, with optimistic price targets contrasting with significant concerns about the protocol's financial runway and governance, often in comparison to rivals like AAVE.

Bitwise 10 Crypto Index ETF - Common Shares Of Beneficial Interest

Bitwise 10 Crypto Index Fund

Bitwise 10 Crypto Index Fund is currently a focal point of intense community debate, primarily driven by a dominant bearish narrative forecasting a severe 'crypto winter' and Bitcoin plummeting to $20,000 by late 2026, based on historical 4-year cycles. Conversely, some investors highlight BITW's significant discount to its Net Asset Value and its ongoing efforts to convert to an ETP structure as potential catalysts for future gains, amidst widespread frustration over its market performance.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending following promising preliminary Phase 3 open-label data indicating a significant reduction in breast cancer recurrence rates, which is driving substantial bullish sentiment. The community is actively discussing the therapy's expansive market potential and the strong confidence of insiders, fueling high anticipation for a potential short squeeze amidst extremely high borrow rates and a tight share float.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is currently soaring after securing FDA approval for YARTEMLEA, a groundbreaking first-in-class therapy for transplant-associated thrombotic microangiopathy (TA-TMA), a previously untreatable and often fatal condition. This pivotal approval, combined with an existing multi-billion dollar licensing deal with Novo Nordisk and significant short interest, has ignited immense excitement among investors who anticipate substantial long-term growth and a potential short squeeze. The community is actively discussing the company's strong de-risked financial position and the drug's unique market position, with many seeing this as the start of a new era for Omeros.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is currently trending following the FDA approval of AQVESME (mitapivat) for anemia in alpha- or beta-thalassemia, marking it as the only approved therapy for these indications. This significant regulatory win is driving positive community discussion, with many anticipating the expanded market opportunity for the company's rare disease drug.

OpGen, Inc. is a precision medicine company, which engages in the power of molecular diagnostics and informatics to help combat infectious disease. It focuses on the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Clarksburg, MD.

Opgen Inc

OPGN is trending amid strong community optimism following recent SEC filings that signal progress toward NASDAQ relisting and highlight its strategic pivot to an AI-driven FinTech platform, CapForce. Investors are actively discussing this transformation from biotech to a high-growth financial sector, with many anticipating a substantial recovery backed by major shareholder AEI Capital, despite current low trading volume.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending following the FCC's decision to ban Chinese-made drones and the passage of the NDAA, which is expected to significantly boost spending on American defense technology. The community is actively debating the company's strong production capacity for its Black Widow drones and the promising outlook for its Blue Ops Unmanned Surface Vessels, while also expressing impatience for firm contract announcements and caution over past management communications.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust ($GBTC) is experiencing heightened discussion as strong bearish sentiment dominates the crypto community, predicting a prolonged "crypto winter" for Bitcoin based on historical 4-year halving cycles. Many foresee substantial price declines due to perceived lack of underlying value, while a smaller group counters that fundamentals remain strong and current FUD is market manipulation. This intense divergence of opinion, coupled with broader macroeconomic concerns, is driving significant conversation around the entire crypto sector.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Trust - ProShares Ultra Silver

ProShares Ultra Silver ($AGQ) is a major talking point, fueled by strong community conviction around silver's critical industrial demand from AI and EV sectors, alongside impending Chinese export restrictions and persistent structural supply deficits. Many foresee a historic "silver squeeze" to rebalance its value against gold, with significant upside potential, though some traders remain cautious of market manipulation and short-term overbought conditions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Actionable Trade Alert for $TROW:

Market Context: $TROW is currently trading at $105.17, showing strong momentum but is overbought with an RSI of 72.88. The price is above the 30-day MA of $102.26 and the 50-day MA of $103.04, indicating bullish sentiment. However, the high of $109.19 suggests a potential resistance level.

Directional Bias: The strong RSI indicates overbought conditions, which could lead to a pullback. However, the price action above key moving averages supports a bullish outlook in the short term.

Trade Plan:
- Suggested Entry: $105.17
- Stop Loss: $102.00 (below the 30-day MA)
- Take Profit Targets:
  1. Target 1: $107.00 (1.73% ROI)
  2. Target 2: $108.00 (2.65% ROI)
  3. Target 3: $123.00 (17% ROI)

Monitor the price action closely, as a break below the 30-day MA could trigger the stop loss. 

For more insights, visit https://privateprofiteers.com.

https://privateprofiteers.com

Privateprofiteers

Private Profiteers | Elite Stock Analysis

StockTwits Web

T. Rowe Price Group Inc.

 is currently trading at $105.17, showing strong momentum but is overbought with an RSI of 72.88. The price is above the 30-day MA of $102.26 and the 50-day MA of $103.04, indicating bullish sentiment. However, the high of $109.19 suggests a potential resistance level.

Directional Bias: The strong RSI indicates overbought conditions, which could lead to a pullback. However, the price action above key moving averages supports a bullish outlook in the short term.

Trade Plan:
- Suggested Entry: $105.17
- Stop Loss: $102.00 (below the 30-day MA)
- Take Profit Targets:
  1. Target 1: $107.00 (1.73% ROI)
  2. Target 2: $108.00 (2.65% ROI)
  3. Target 3: $123.00 (17% ROI)

Monitor the price action closely, as a break below the 30-day MA could trigger the stop loss. 

For more insights, visit 